1. Home
  2. EU vs LCTX Comparison

EU vs LCTX Comparison

Compare EU & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo enCore Energy Corp.

EU

enCore Energy Corp.

HOLD

Current Price

$1.61

Market Cap

361.2M

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.32

Market Cap

388.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EU
LCTX
Founded
2009
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
361.2M
388.6M
IPO Year
2011
1996

Fundamental Metrics

Financial Performance
Metric
EU
LCTX
Price
$1.61
$1.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$4.00
$6.25
AVG Volume (30 Days)
2.8M
1.3M
Earning Date
05-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
11.76
N/A
EPS
0.03
N/A
Revenue
$43,155,000.00
$14,556,000.00
Revenue This Year
$212.11
$109.40
Revenue Next Year
$29.88
N/A
P/E Ratio
$52.83
N/A
Revenue Growth
N/A
53.24
52 Week Low
$1.34
$0.65
52 Week High
$4.19
$2.09

Technical Indicators

Market Signals
Indicator
EU
LCTX
Relative Strength Index (RSI) 44.87 44.36
Support Level $1.34 $1.14
Resistance Level $2.17 $1.80
Average True Range (ATR) 0.10 0.08
MACD 0.01 0.01
Stochastic Oscillator 65.00 55.56

Price Performance

Historical Comparison
EU
LCTX

About EU enCore Energy Corp.

enCore Energy Corp together with its subsidiary, is principally engaged in the acquisition, exploration, development and extraction of uranium resource properties in the United States. The Company is focused on the extraction of domestic uranium in the United States. The Company utilizes the In-Situ Recovery technology (ISR) to provide necessary fuel for the generation of clean, reliable, and carbon-free nuclear energy.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Share on Social Networks: